find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
Leukemia
Phase I
Enrolling
nct/study# NCT06001788 / KO-MEN-008
Phase 1 trial sponsored by Kura Oncology, Inc. under Protocol Number KO-MEN-008 entitled Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia. Attached for your consideration is a high-level overview of the trial.
Learn More
Leukemia
Phase III
Enrolling
nct/study# NCT06479135 / KRT-232-115
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) That have a Suboptimal Response to Ruxolitinib.
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / 2018-0158
Outcomes of Patients with Newly Diagnosed Peripheral T-cell Lymphoma Treated with Aggressive Chemotherapy, including Cutaneous Gamma-Delta T cell Lymphoma
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / 2018-0227
Characteristics and Outcomes of Patients with Marginal Zone Lymphoma: A Retrospective Study
Learn More
Lymphoma
N/A
Enrolling
Lymphoma
N/A
Enrolling
nct/study# N/A / 2019-0246
Outcomes of Current Front-Line Therapy Regimens in Elderly Patients with Classical Hodgkin’s Lymphoma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.